Clinical Trials Browser

Phase 2 × Turcot syndrome × Plasma cell × Clear all

NCT04439214 2021-04-06

Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)

Phase 2 Completed

47 enrolled 10 charts

LymphoidOther hematologic neoplasmPlasma cell

Turcot syndrome, Lymphoma, Multiple Myeloma, Hematologic Neoplasms